Core Insights - argenx SE announced positive topline results from the Phase 3 ADAPT OCULUS study for VYVGART in adults with ocular myasthenia gravis (oMG) [2][3] - The study met its primary endpoint, demonstrating a statistically significant improvement in Myasthenia Impairment Index (MGII) scores for patients treated with VYVGART compared to placebo [3][8] - VYVGART was well tolerated with a favorable safety profile, showing no new safety concerns [4][5] Study Results - The ADAPT OCULUS study showed a mean change from baseline of 4.04 points in MGII PRO scores for VYVGART-treated patients versus 1.99 points for placebo [3][8] - The primary endpoint was achieved with a p-value of 0.012, indicating statistical significance [3][8] - Key ocular symptoms such as diplopia and ptosis were significantly reduced in patients receiving VYVGART [3] Study Design - ADAPT OCULUS is a Phase 3, randomized, double-blind, placebo-controlled study involving 141 adult patients with ocular MG across North America, Europe, and Asia-Pacific [6][7] - Participants received four weekly injections of VYVGART or placebo, followed by a 4-week follow-up [6] - The study included both seropositive and seronegative patients for AChR-Ab [7] Implications for Treatment - The results from the ADAPT OCULUS study support a planned Supplemental Biologics License Application (sBLA) to the U.S. FDA to expand VYVGART's label to include oMG [8] - This study is the first registrational trial specifically designed for a targeted therapy for ocular myasthenia gravis, addressing a significant unmet need in the MG community [5][8] About Ocular Myasthenia Gravis - Ocular myasthenia gravis is characterized by muscle weakness affecting the eyes and eyelids, with symptoms including ptosis and diplopia [27] - Approximately 80% of myasthenia gravis patients initially present with ocular symptoms, and up to 92% experience ocular involvement during their disease course [27] - There are currently no approved targeted therapies specifically for oMG, highlighting the need for new treatment options [27] Company Overview - argenx is a global immunology company focused on developing treatments for severe autoimmune diseases [28] - The company is advancing its portfolio of antibody-based medicines and has developed the first approved neonatal Fc receptor (FcRn) blocker [28]

Core Insights - The FDA has accepted a supplemental Biologics License Application (sBLA) for VYVGART (efgartigimod alfa-fcab) for treating adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG), with a target action date of May 10, 2026 [1][2] Company Overview - Argenx SE is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [1][18] - The company is developing VYVGART, the first approved neonatal Fc receptor (FcRn) blocker, and is exploring its potential across various serious autoimmune diseases [18] Clinical Study Details - The sBLA is supported by data from the Phase 3 ADAPT SERON study, which demonstrated a statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score compared to placebo after four weeks [2][3] - The study included 119 participants and evaluated the safety and efficacy of efgartigimod in adults with AChR-Ab seronegative gMG across multiple regions [5] Efficacy and Safety - In the overall population, patients treated with VYVGART showed a clinically meaningful improvement of 3.35 points in MG-ADL total score at week 4 [3] - VYVGART was well-tolerated, with a safety profile consistent with previous studies, and no new safety concerns were identified [4] Patient Population - Approximately 20% of gMG patients are AChR-Ab seronegative, lacking detectable antibodies against AChR, MuSK, or LRP4, and currently have no approved treatments available [7][8]